Co. are launching Ambys Medicines with $140 million to develop regenerative medicines for liver diseases. Some 3.9 million U.S. adults have been diagnosed with liver disease, according to the Centers for Disease Control and Prevention. Ambys, formed by Third Rock and Takeda this year, is capitalizing on improved understanding of liver biology and advances in cell and gene therapy to treat liver conditions.

Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.

Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported that its operating profit halved from the year-ago quarter, when the drugmaker had booked gains from asset sales. Takeda has sold off assets it sees as non-core or underperforming, with Chief Executive Christophe Weber saying on Tuesday he was open to further disposals as the drugmaker looks to shore up its stretched finances. Many of Takeda's top-performing drugs posted stronger sales in the first quarter, but the company is facing a weak late-stage pipeline.

Co. (4502.TO) told Dow Jones Newswires on Tuesday it has no plans to increase prices in the U.S. in 2018, the latest major drugmaker to take such a step. Last week, Novartis AG (NOVN.EB) and Merck & Co. (MRK) made similar pledges. Novartis said it wouldn’t raise U.S. drug prices, and Merck said it would lower them for certain drugs.

Takeda Pharmaceutical Co. sees China becoming a “core country” for its global growth strategy and is optimistic its $62 billion acquisition of Shire Plc will win approval by the country’s regulators. Takeda is preparing to begin selling seven new drugs in China in the next five years, more than in any other region, while working to secure reimbursement for them under the country’s medical insurance program, Chief Executive Officer Christophe Weber said in an interview in Beijing. “There’s no reason in the long term China shouldn’t be our second-biggest business in the world,” Weber said.

U.S. stock futures rose modestly on Tuesday, July 10, and global stocks traded mostly higher following one of the strongest sessions on Wall Street in over a month, as investors slowly switched their focus to the upcoming corporate earnings season.

Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc (SHP.L), taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

Embedded in the sleek metallic and cypress interior of Takeda Pharmaceutical Co.’s new global headquarters in Tokyo are stylized Japanese characters for words like life, water and light. Melding futuristic design with traditional Japanese elements highlights the balancing act facing Chief Executive Officer Christophe Weber: showing he can honor the 237-year-old drugmaker’s Japanese heritage as he tries to complete the biggest deal in Takeda’s history -- the $62 billion takeover of Shire Plc. “He’s very quick to say they’re still a Japanese company, but at the same time making a point to say they’re not Japanese because they have a very international, global executive team,” said John W. Carlson, chair of the health-care committee at the American Chamber of Commerce in Japan.

A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favour, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favor, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

Christophe Weber, the first foreign-born chief executive officer of Japan’s Takeda Pharmaceutical Co., last month inked a $62 billion takeover of rare-disease drugmaker Shire Plc. The deal will reshape the 237-old, Osaka-based company into a global powerhouse. In a recent interview in Manhattan, the French-born CEO talked about exciting areas of research and the potential of China. It used to take years to get the Essential Drug List [a list of medicines covered by the national medical insurance] updated in China.

Christophe Weber says growth and innovation are the metrics to success in Takeda Pharmaceutical Co.’s $62 billion purchase of Shire Plc. The first order of business is bringing global shareholders around to Japan’s biggest-ever outbound takeover. The Takeda chief executive officer is facing a 21 percent drop in the stock price since the company disclosed its interest in March, while Shire is trading 9 pounds ($12) below the offer price of roughly 49 pounds a share. In an interview at Takeda’s new Tokyo headquarters, the French-born CEO discusses his push to sell the deal overseas -- and in Japan -- and plans to integrate the 237-year-old drugmaker with a London-listed company with mostly U.S.-based operations.

A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion (46.4 billion pounds) acquisition of London-listed Shire Plc (SHP.L) at an extraordinary general meeting, a leading member of the group told Reuters on Monday. Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself. The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.

A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L) at an extraordinary general meeting, a leading member of the group told Reuters on Monday. Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself. The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.